Evidence map›Paper›PMID 40018493›Full record

ArticleCureus2025

Flexor Tenosynovitis as the Sole Initial Presentation of Anti-synthetase Syndrome: A Case Report.

Taylor Kann, Richa Purohit, Mariana Aziz, Marie Rivera-Zengotita, Maria Farooq

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Taylor KannRheumatology, University of Central Florida College of Medicine, Orlando, USA.
Richa PurohitInternal Medicine, Orlando Internal Medicine, Orlando, USA.
Mariana AzizInternal Medicine, University of Central Florida College of Medicine, Orlando, USA.
Marie Rivera-ZengotitaPathology, University of Florida, Gainesville, USA.
Maria FarooqRheumatology, University of Central Florida College of Medicine, Orlando, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-synthetase syndrome (ASS) is a rare autoimmune disorder characterized by interstitial lung disease (ILD), myositis, and arthritis, primarily associated with antibodies, such as anti-Jo-1, that target the t-ribonucleic acid (tRNA) synthetase enzymes. This case report describes a 45-year-old man who presented with isolated flexor tenosynovitis and bilateral hand pain, later diagnosed with anti-Jo-1 positive ASS. Initially, the patient's symptoms were attributed to a trivial injury, but subsequent imaging and laboratory evaluations revealed tenosynovitis without signs of inflammatory arthritis. Positive anti-Jo-1 antibodies and later elevated creatine kinase (CK) levels indicated the development of myositis, supported by magnetic resonance imaging (MRI) findings and muscle biopsies showing mild inflammatory features. The patient was treated with prednisone and mycophenolate mofetil, resulting in significant clinical improvement and resolution of symptoms. This case highlights an atypical presentation of ASS, with isolated tenosynovitis as an initial symptom, which is not commonly documented in the literature. The findings underscore the importance of considering ASS in patients with unexplained inflammatory symptoms and highlight the role of comprehensive clinical evaluation and antibody testing in guiding diagnosis. By recognizing the variable clinical manifestations of ASS, clinicians can facilitate earlier diagnosis and prompt treatment, improving patient outcomes.

Indexed as

anti-jo-1 antibodiesanti-synthetase (as) syndromeflexor tenosynovitisimmune-mediated inflammatory myopathymechanic’s hands

Identifiers

PMID40018493
PMCPMC11867200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.